Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137


Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials.

Lorenzetti R, Zullo A, Ridola L, Diamanti AP, Laganà B, Gatta L, Migliore A, Armuzzi A, Hassan C, Bruzzese V.

Ann Med. 2014 Nov;46(7):547-54. doi: 10.3109/07853890.2014.941919. Review.


T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.

Deepak P, Sifuentes H, Sherid M, Stobaugh D, Sadozai Y, Ehrenpreis ED.

Am J Gastroenterol. 2013 Jan;108(1):99-105. doi: 10.1038/ajg.2012.334.


Tumor necrosis factor α antagonist-associated psoriasis in inflammatory diseases: an analysis of the FDA adverse event reporting system.

Kip KE, Swoger JM, Grandinetti LM, Barrie AM 3rd, Greer JB, Regueiro MD.

Inflamm Bowel Dis. 2013 May;19(6):1164-72. doi: 10.1097/MIB.0b013e31828075bd.


Risk of tuberculosis with anti-tumor necrosis factor-α therapy: substantially higher number of patients at risk in Asia.

Navarra SV, Tang B, Lu L, Lin HY, Mok CC, Asavatanabodee P, Suwannalai P, Hussein H, Rahman MU.

Int J Rheum Dis. 2014 Mar;17(3):291-8. doi: 10.1111/1756-185X.12188.


Tuberculosis in anti-TNF-α treated patients remains a problem in countries with an intermediate incidence: analysis of 25 patients matched with a control population.

Abreu C, Magro F, Santos-Antunes J, Pilão A, Rodrigues-Pinto E, Bernardes J, Bernardo A, Magina S, Vilas-Boas F, Lopes S, Macedo G, Sarmento A.

J Crohns Colitis. 2013 Nov;7(10):e486-92. doi: 10.1016/j.crohns.2013.03.004.


Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry.

Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Bréban M, Pallot-Prades B, Pouplin S, Sacchi A, Chichemanian RM, Bretagne S, Emilie D, Lemann M, Lortholary O, Mariette X; Research Axed on Tolerance of Biotherapies Group..

Arthritis Rheum. 2009 Jul;60(7):1884-94. doi: 10.1002/art.24632. Erratum in: Arthritis Rheum. 2009 Aug;60(8):2540. Lorthololary, O [corrected to Lortholary, O].


The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials.

Dommasch ED, Abuabara K, Shin DB, Nguyen J, Troxel AB, Gelfand JM.

J Am Acad Dermatol. 2011 Jun;64(6):1035-50. doi: 10.1016/j.jaad.2010.09.734. Review.


The Risk of Tuberculosis in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor-α Antagonist: A Metaanalysis of Both Randomized Controlled Trials and Registry/Cohort Studies.

Ai JW, Zhang S, Ruan QL, Yu YQ, Zhang BY, Liu QH, Zhang WH.

J Rheumatol. 2015 Dec;42(12):2229-37. doi: 10.3899/jrheum.150057. Review.


The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.

Suwannalai P, Auethavekiat P, Udomsubpayakul U, Janvitayanujit S.

Int J Rheum Dis. 2009 Jul;12(2):118-24. doi: 10.1111/j.1756-185X.2009.01393.x.


Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review.

Dulai PS, Thompson KD, Blunt HB, Dubinsky MC, Siegel CA.

Clin Gastroenterol Hepatol. 2014 Sep;12(9):1443-51; quiz e88-9. doi: 10.1016/j.cgh.2014.01.021. Review.


Risk of tuberculosis in patients treated with anti-tumor necrosis factor therapy: a nationwide study in South Korea, a country with an intermediate tuberculosis burden.

Jung SM, Ju JH, Park MS, Kwok SK, Park KS, Kim HY, Yim HW, Park SH.

Int J Rheum Dis. 2015 Mar;18(3):323-30. doi: 10.1111/1756-185X.12530.


Safe re-administration of tumor necrosis factor-alpha (TNFα) inhibitors in patients with rheumatoid arthritis or ankylosing spondylitis who developed active tuberculosis on previous anti-TNFα therapy.

Suh YS, Kwok SK, Ju JH, Park KS, Park SH, Yoon CH.

J Korean Med Sci. 2014 Jan;29(1):38-42. doi: 10.3346/jkms.2014.29.1.38. Erratum in: J Korean Med Sci. 2014 Mar;29(3):460.


Differential risk of tuberculosis reactivation among anti-TNF therapies is due to drug binding kinetics and permeability.

Fallahi-Sichani M, Flynn JL, Linderman JJ, Kirschner DE.

J Immunol. 2012 Apr 1;188(7):3169-78. doi: 10.4049/jimmunol.1103298.


Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature.

Cullen G, Kroshinsky D, Cheifetz AS, Korzenik JR.

Aliment Pharmacol Ther. 2011 Dec;34(11-12):1318-27. doi: 10.1111/j.1365-2036.2011.04866.x. Review.


Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection.

Gómez-Reino JJ, Carmona L, Angel Descalzo M; Biobadaser Group..

Arthritis Rheum. 2007 Jun 15;57(5):756-61.


Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.

Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, Montero D, Pascual-Gómez E, Mola EM, Carreño L, Figueroa M; BIOBADASER Group..

Arthritis Rheum. 2005 Jun;52(6):1766-72.


Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease.

Williams CJ, Peyrin-Biroulet L, Ford AC.

Aliment Pharmacol Ther. 2014 Mar;39(5):447-58. doi: 10.1111/apt.12624. Review.


Is it safe to use anti-TNF-α agents for tuberculosis in children suffering with chronic rheumatic disease?

Kilic O, Kasapcopur O, Camcioglu Y, Cokugras H, Arisoy N, Akcakaya N.

Rheumatol Int. 2012 Sep;32(9):2675-9. doi: 10.1007/s00296-011-2030-8.


Supplemental Content

Support Center